How India Exports Extract to the World

The U.S. Food and Drug Administration (FDA) maintains the Orange Book, which lists approved drug products along with therapeutic equivalence evaluations. For products classified under HS Code 30049099, the Orange Book provides detailed information on approved Abbreviated New Drug Applications (ANDAs), including the number of approvals, recent approval dates, and any import alerts. This resource is essential for understanding the regulatory pathway for these products in the U.S. market.

Given the substantial number of active Indian exporters—292 as per TransData Nexus's proprietary trade data—it's evident that Indian pharmaceutical companies are significantly engaged in the U.S. market. This underscores the importance of adhering to FDA regulations and staying informed about any changes in the regulatory landscape to ensure continued market access.

In the European Union (EU) and the United Kingdom (UK), medicinal products must obtain marketing authorization before they can be marketed. The European Medicines Agency (EMA) oversees this process within the EU, while the Medicines and Healthcare products Regulatory Agency (MHRA) is responsible in the UK. Both agencies require compliance with Good Manufacturing Practice (GMP) standards to ensure product quality and safety.

For products under HS Code 30049099, manufacturers must submit comprehensive dossiers demonstrating efficacy, safety, and quality. Additionally, adherence to EU GMP guidelines is mandatory, and facilities may be subject to inspections by regulatory authorities to verify compliance.

The World Health Organization (WHO) maintains the Model List of Essential Medicines, which identifies medications considered essential for basic healthcare systems. Inclusion in this list indicates a medicine's importance in addressing public health needs. Furthermore, the WHO Prequalification Programme assesses the quality, safety, and efficacy of medicinal products, facilitating their procurement by UN agencies and other organizations.

Products under HS Code 30049099 must also comply with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). These standards ensure consistency in quality and efficacy across different markets.

In India, the Central Drugs Standard Control Organization (CDSCO) classifies drugs into various schedules under the Drugs and Cosmetics Act. Products under HS Code 30049099 are typically classified under Schedule H, indicating that they are prescription drugs requiring a doctor's prescription for sale.

The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines under the Drug Price Control Order (DPCO). Manufacturers must comply with these pricing regulations to ensure affordability. Additionally, for exporting such products, obtaining a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) is often required, ensuring that the export complies with national policies and international agreements.

Patent protection and market exclusivity are critical factors influencing the availability of generic versions of pharmaceutical products. The FDA's Orange Book lists patents and exclusivity periods associated with approved drug products, providing transparency for generic manufacturers. Understanding the patent landscape is essential for assessing the potential for generic competition and planning market entry strategies.

In the past 12 months, several notable developments have occurred in the pharmaceutical industry:

1. April 2025: The FDA updated its Orange Book to enhance clarity on reference listed drugs (RLDs) and reference standards, aiding generic manufacturers in identifying appropriate comparators for bioequivalence studies.

2. July 2025: The EMA implemented revised guidelines on the assessment of bioequivalence, impacting the approval process for generic medicines in the EU.

3. September 2025: The WHO added new medicines to its Model List of Essential Medicines, reflecting evolving global health priorities.

4. November 2025: The NPPA revised ceiling prices for several essential medicines under the DPCO, affecting pricing strategies for manufacturers in India.

5. January 2026: The CDSCO introduced new guidelines for the export of pharmaceutical products, streamlining the NOC process for exporters.

These developments underscore the dynamic nature of the pharmaceutical regulatory environment and the importance of staying informed to navigate market challenges effectively.

India's pharmaceutical industry, often referred to as the "pharmacy of the world," heavily relies on China for Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs). Approximately 60–70% of India's APIs are sourced from China, creating a significant dependency. This reliance exposes the supply chain to vulnerabilities, as any disruption in Chinese production—due to environmental regulations, geopolitical tensions, or other factors—can lead to shortages and price volatility in the Indian pharmaceutical sector.

In response, the Indian government has initiated measures to reduce this dependency. In October 2024, under the Production Linked Incentive (PLI) scheme, two greenfield plants were inaugurated to manufacture critical molecules like Penicillin G, 6-Aminopenicillanic acid (6-APA), and Clavulanic Acid. These efforts aim to bolster domestic production and decrease import reliance by half. However, the effectiveness of these initiatives in mitigating supply chain risks remains to be fully realized.

The export market for "Extract" from India is characterized by a moderate level of supplier concentration. The top five exporters account for 34.5% of total exports, with DABUR INDIA LIMITED leading at a 9.0% share. While this indicates a relatively diversified supplier base, the presence of a few dominant players suggests potential risks if any of these key exporters face operational disruptions.

To address such risks, the Indian government's PLI scheme aims to enhance domestic manufacturing capabilities and reduce reliance on a limited number of suppliers. By incentivizing a broader range of manufacturers to produce essential APIs and KSMs, the scheme seeks to distribute production more evenly across the industry, thereby mitigating single-source risks.

Recent geopolitical events have significantly impacted global supply chains. The closure of the Strait of Hormuz in February 2026, following attacks on Iran, disrupted the movement of oil and other critical goods, including pharmaceuticals. This blockade led to delays and increased costs for shipments originating from India and destined for various global markets.

Additionally, tensions in the Red Sea and the Suez Canal have forced shipping companies to reroute vessels around Africa's Cape of Good Hope, resulting in longer transit times and higher fuel expenses. These disruptions have caused delays in the delivery of pharmaceuticals and other essential goods, highlighting the vulnerability of global supply chains to geopolitical instability.

• Diversify Supplier Base: Encourage the development of multiple domestic suppliers for critical APIs and KSMs to reduce dependency on a single source.

• Enhance Domestic Production: Continue to invest in and expand initiatives like the PLI scheme to strengthen India's internal manufacturing capabilities.

• Develop Alternative Shipping Routes: Establish and utilize alternative logistics pathways to mitigate the impact of disruptions in key maritime chokepoints.

• Strengthen Regulatory Compliance: Ensure that domestic manufacturers adhere to international quality standards to maintain a competitive edge and reduce reliance on foreign suppliers.

• Monitor Geopolitical Developments: Implement a robust monitoring system to anticipate and respond to geopolitical events that may affect supply chains.

RISK_LEVEL: MEDIUM